FNYS
MACK

First New York Securities’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

First New York Securities’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-477
Closed -$23.8K – 249
2016
Q3 		$23.8K Buy
+477
New +$19.8K 0.02% 160
2014
Q4 		– Sell
-318
Closed -$21.9K – 601
2014
Q3 		$21.9K Buy
+318
New +$17K 0.02% 330

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

First New York Securities's MACK Position: Q4 2016 in Review

First New York Securities sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q4 2016, closing a stake of 477 shares — an estimated $23.8K sold.

First New York Securities first reported a position in MACK in Q3 2014 and held it in 2 quarters. The position peaked at $23.8K in Q3 2016. 136 funds tracked by Wall St. Rank hold MACK as of Q4 2016.

  • First New York Securities reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q4 2016 after selling out during the quarter.
  • First New York Securities sold 477 Merrimack Pharmaceuticals, Inc. shares in Q4 2016, an estimated $23.8K.
  • First New York Securities first reported a position in Merrimack Pharmaceuticals, Inc. in Q3 2014 and held it in 2 quarters.
  • First New York Securities's Merrimack Pharmaceuticals, Inc. position peaked at $23.8K in Q3 2016.
  • 136 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q4 2016.

Based on First New York Securities's 13F filing for Q4 2016, filed 7 Feb 2017.